Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sundrug Co ( (JP:9989) ) has provided an announcement.
Sundrug reported consolidated net sales of ¥635.7 billion for the nine months to Dec. 31, 2025, up 5.3% year on year, with operating profit rising 4.9% to ¥36.5 billion and profit attributable to owners of parent edging 1.7% higher to ¥24.2 billion. The company’s financial position remained solid, with total assets increasing to ¥470.2 billion and an equity ratio of 59.3%, while management kept its full-year forecast unchanged, targeting ¥850 billion in net sales, modest profit growth and a slight increase in the annual dividend to ¥131 per share, underscoring steady but slowing earnings momentum for shareholders.
The most recent analyst rating on (JP:9989) stock is a Hold with a Yen4500.00 price target. To see the full list of analyst forecasts on Sundrug Co stock, see the JP:9989 Stock Forecast page.
More about Sundrug Co
Sundrug Co., Ltd. is a Japan-based operator of drugstores and related retail outlets listed on the Tokyo Stock Exchange. The company focuses on pharmacy and daily necessities sales, generating stable consumer-driven revenue across its nationwide store network under Japanese GAAP reporting standards.
Average Trading Volume: 286,873
Technical Sentiment Signal: Buy
Current Market Cap: Yen494.8B
Find detailed analytics on 9989 stock on TipRanks’ Stock Analysis page.